sustain 6 trial semaglutide 🔑 SUSTAIN-6 (NEJM 2016) — the safety that became a landmark., In 3,297 patients with type 2 diabetes at high CV risk, reduced:, • 3-point MACE 26% (HR 0.74), • Nonfatal stroke 39% Cardiovascular Outcomes, Safety, and Tolerability
Pay in 4 interest-free payments of $6.88 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3


























